Quantcast

Latest Sipuleucel-T Stories

2010-08-05 10:26:00

RESEARCH TRIANGLE PARK, NC, Aug.

2010-08-03 15:14:00

SEATTLE, Aug. 3 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the quarter ended June 30, 2010. Revenue for the quarter ended June 30, 2010 was $2.8 million compared to $25,000 for the quarter ended June 30, 2009.

2010-07-28 16:02:00

SEATTLE, July 28 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced today the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE® (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer (mCRPC).

2010-07-20 09:00:00

WALTHAM, Mass., July 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch and uptake of nine emerging therapies will drive the prostate cancer drug market to more than double from nearly $4 billion in 2009 to $8.4 billion in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

2010-07-12 06:30:00

SEATTLE, July 12 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) management will host a conference call on Tuesday, August 3, 2010 at 4:30 p.m. ET to review second quarter financial results.

2010-06-30 18:48:00

SEATTLE, June 30 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced that the Centers for Medicare and Medicaid Services (CMS) today initiated a National Coverage Analysis (NCA) of PROVENGE® (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC).

2010-06-07 14:28:00

BETHESDA, Md., June 7 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT") (OTC Bulletin Board: NWBO), developer of the DCVax® personalized cancer vaccine, today announced the release of a new detailed report by Pharmaceuticals and Biotech Analyst Dr.

2010-06-02 11:00:00

SEATTLE, June 2 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that David C. Stump, M.D., has been elected to the Company's Board of Directors. Dr. Stump is currently executive vice president of research and development for Human Genome Sciences, Inc.

2010-05-31 13:00:00

SEATTLE and SAN FRANCISCO, May 31 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the presentation of safety data from the integrated analysis of four randomized PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in prostate cancer at the 105th Annual Scientific Meeting of the American Urological Association (AUA) in San Francisco.

2010-05-20 17:00:00

SEATTLE and CHICAGO, May 20 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the upcoming presentation of data from integrated analyses of three Phase 3 PROVENGE® (sipuleucel-T) clinical trials of an autologous cellular immunotherapy in advanced prostate cancer, to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago on Monday, June 7 at 8:00 a.m.


Word of the Day
aphotic
  • Having no light.
  • Of or relating to the region of a body of water that is not reached by sunlight and in which photosynthesis is unable to occur.
The word 'aphotic' comes from Greek roots meaning 'without' and 'light'.
Related